These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14520119)

  • 1. Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia.
    Okada T; Toichi M; Sakihama M
    J Clin Psychopharmacol; 2003 Oct; 23(5):441-7. PubMed ID: 14520119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesia and eye tracking dysfunction in young schizophrenic patients - a pilot study.
    Salokangas RK; Syvälahti E; Lehtinen I
    Methods Find Exp Clin Pharmacol; 1983; 5(4):263-9. PubMed ID: 6136641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.
    Ogino S; Miyamoto S; Miyake N; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Jan; 68(1):37-49. PubMed ID: 24102938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of psychosis in elderly patients with parkinsonism.
    Hasnain M; Vieweg WV; Baron MS; Beatty-Brooks M; Fernandez A; Pandurangi AK
    Am J Med; 2009 Jul; 122(7):614-22. PubMed ID: 19559160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between cardiovagal modulation and psychotic state in patients with paranoid schizophrenia.
    Bär KJ; Wernich K; Boettger S; Cordes J; Boettger MK; Löffler S; Kornischka J; Agelink MW
    Psychiatry Res; 2008 Jan; 157(1-3):255-7. PubMed ID: 17919737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
    Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive insight and acute psychosis in schizophrenia.
    Bora E; Erkan A; Kayahan B; Veznedaroglu B
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):634-9. PubMed ID: 18081624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive burden of anticholinergic medications in psychotic disorders.
    Eum S; Hill SK; Rubin LH; Carnahan RM; Reilly JL; Ivleva EI; Keedy SK; Tamminga CA; Pearlson GD; Clementz BA; Gershon ES; Keshavan MS; Keefe RSE; Sweeney JA; Bishop JR
    Schizophr Res; 2017 Dec; 190():129-135. PubMed ID: 28390849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of efferent vagal activity in acute schizophrenia.
    Bär KJ; Letzsch A; Jochum T; Wagner G; Greiner W; Sauer H
    J Psychiatr Res; 2005 Sep; 39(5):519-27. PubMed ID: 15992561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine use in a patient with chronic schizophrenia and severe parkinsonism.
    Stoner SC; Lea JW; Wolf AL; Berges AA
    Pharmacotherapy; 2005 Nov; 25(11):1651-5. PubMed ID: 16232027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychotic symptoms and paranoid ideation in a population-based sample of 95-year-olds.
    Ostling S; Börjesson-Hanson A; Skoog I
    Am J Geriatr Psychiatry; 2007 Dec; 15(12):999-1004. PubMed ID: 18056818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insight in schizophrenia: assessment of 31 patients with different scales].
    Travers D; Levoyer D; Millet B
    Encephale; 2008 Jan; 34(1):66-72. PubMed ID: 18514153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizoaffective disorders are psychotic mood disorders; there are no schizoaffective disorders.
    Lake CR; Hurwitz N
    Psychiatry Res; 2006 Aug; 143(2-3):255-87. PubMed ID: 16857267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 20. Rumination and negative symptoms in schizophrenia.
    Halari R; Premkumar P; Farquharson L; Fannon D; Kuipers E; Kumari V
    J Nerv Ment Dis; 2009 Sep; 197(9):703-6. PubMed ID: 19752652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.